Online citations, reference lists, and bibliographies.
← Back to Search

The Transcription Factor ZEB1 Promotes Chemoresistance In Prostate Cancer Cell Lines

O. Orellana-Serradell, D. Herrera, E. Castellón, H. Contreras
Published 2019 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
One of the factors promoting tumoral progress is the abnormal activation of the epithelial–mesenchymal transition (EMT) program which has been associated with chemoresistance in tumoral cells. The transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), a key EMT activator, has recently been related to docetaxel resistance, the main chemotherapeutic used in advanced prostate cancer treatment. The mechanisms involved in this protective effect are still unclear. In a previous work, we demonstrated that ZEB1 expression induced an EMT-like phenotype in prostate cancer cell lines. In this work, we used prostate cancer cell lines 22Rv1 and DU145 to study the effect of ZEB1 modulation on docetaxel resistance and its possible mechanisms. The results showed that ZEB1 overexpression conferred to 22Rv1 cell resistance to docetaxel while its silencing made DU145 cells more sensitive to it. Analysis of resistance markers showed no presence of ATP-binding cassette subfamily B member 1 (MDR1) and no changes in breast cancer resistance protein (BCRP) or ATP-binding cassette subfamily C member 10 (MRP7). However, a correlation between ZEB1, multidrug resistance-associated protein 1 (MRP1), and ATP-binding cassette subfamily C member 4 (MRP4) expression was observed. MRP4 inhibition, using MK571, resensitized cells with ZEB1 overexpression to docetaxel treatment. In addition, modulation of ZEB1 and subsequent change in MRP4 expression correlated with a lower apoptotic response to docetaxel, characterized by lower B-cell lymphoma 2 (Bcl2), high BCL2-associated X protein (Bax), and high active caspase 3 expression. The response to docetaxel in our model seems to be mediated mainly by activation of the apoptotic death program. Our results showed that modulation of MRP4 could be a mediator of ZEB1-related resistance to docetaxel in prostate cancer, making it a possible marker for chemotherapy response in patients who do not express MDR1.
This paper references
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
A. Raffo (1995)
10.1016/b978-0-323-37643-3.50018-9
Prostate
P. Malone (1995)
10.1200/JCO.1996.14.6.1756
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
I. Tannock (1996)
The expression of drug resistance gene products during the progression of human prostate cancer.
G. F. Sullivan (1998)
10.3322/canjclin.49.1.33
Global cancer statistics
D. Parkin (1999)
Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
I. Lebedeva (2000)
10.3892/IJO.17.6.1077
Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
G. L. David-Beabes (2000)
10.1016/S0304-3835(99)00384-5
Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies.
K. Kawai (2000)
10.1016/S1078-1439(99)00055-1
Expression of the multidrug resistance gene in human prostate cancer.
Bhangal (2000)
10.1038/35094009
The development of androgen-independent prostate cancer
B. Feldman (2001)
10.1038/nrc801
A history of prostate cancer treatment
S. Denmeade (2002)
10.1016/S0169-409X(02)00169-2
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.
A. Schinkel (2003)
10.1124/MOL.64.1.51
Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.
C. Ferlini (2003)
10.1159/000077285
Interference by Anti-Cancer Chemotherapeutic Agents in the MTT-Tumor Chemosensitivity Assay
E. Ulukaya (2004)
10.1056/NEJMOA041318
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
D. Petrylak (2004)
10.1158/1535-7163.MCT-05-0130
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells
D. L. Morse (2005)
10.1007/978-1-59745-035-5_18
Resistance To Taxanes
L. Greenberger (2006)
10.1016/j.febslet.2006.02.020
Mechanisms and strategies to overcome multiple drug resistance in cancer
T. Ozben (2006)
10.3892/IJO.31.2.277
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
H. Kajiyama (2007)
10.1038/sj.onc.1210102
Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis
H. Hernández-Vargas (2007)
10.1245/s10434-007-9583-5
Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells
Ami N. Shah (2007)
10.1200/JCO.2007.12.4008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
D. Berthold (2008)
10.1016/J.BBCAN.2007.10.004
Taxanes, microtubules and chemoresistant breast cancer.
Barbara McGrogan (2008)
microtubules and chemoresistant breast cancer
B T Mcgrogan (2008)
10.1186/1476-4598-8-68
Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75
Melanie Mediavilla-Varela (2009)
10.1007/s10555-009-9194-7
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
D. J. McConkey (2009)
Determining the Predictive Mechanism of Toxicity Using a Single-Well Multiplexed Assay. Promega Corporation; Updated
S Schultz (2009)
Review series the basics of epithelial‐mesenchymal transition
R Kalluri (2009)
10.1158/0008-5472.CAN-10-1447
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
G. Ploussard (2010)
10.2174/138945010791170888
Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.
D. Karnak (2010)
10.1038/nrclinonc.2010.136
Drug resistance in metastatic castration-resistant prostate cancer
B. Šeruga (2011)
10.1186/1476-4598-10-126
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
A. O'Neill (2011)
10.1038/pcan.2011.23
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
E. Antonarakis (2011)
10.1177/1758834012449685
Overcoming docetaxel resistance in prostate cancer: a perspective review
C. Hwang (2012)
10.5732/cjc.011.10326
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
Xue Xue (2012)
10.1186/1471-2407-14-37
Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells
H. Wang (2013)
ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
D. Oprea-Lager (2013)
10.1158/1535-7163.MCT-13-0775
Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
M. Marín-Aguilera (2014)
10.1155/2014/476974
Regulations of P-Glycoprotein/ABCB1/MDR1 in Human Cancer Cells
K. Katayama (2014)
10.1186/s12885-015-1689-8
Frequent down-regulation of ABC transporter genes in prostate cancer
Rita Demidenko (2015)
10.3892/ijo.2015.3084
Epithelial-mesenchymal transition and drug resistance in breast cancer (Review).
Jing Huang (2015)
10.3322/caac.21262
Global cancer statistics, 2012
Lindsey A. Torre (2015)
10.1186/s12916-015-0457-6
Targeting molecular resistance in castration-resistant prostate cancer
T. Chandrasekar (2015)
10.1080/15384101.2015.1006048
ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
P. Zhang (2015)
10.3390/molecules21070965
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
B. Du (2016)
10.1016/S0140-6736(15)01037-5
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
N. James (2016)
10.1002/cncr.31026
Prostate cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study
C. B. Steele (2017)
10.1002/1878-0261.12030
The role of epithelial–mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel‐resistant prostate cancer
Karen Hanrahan (2017)
10.3892/ol.2017.6357
Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancer.
Y. Li (2017)
10.1001/jama.2017.7248
The Diagnosis and Treatment of Prostate Cancer: A Review
M. Litwin (2017)
10.1158/0008-5472.CAN-17-2476
Pleiotropic Roles for ZEB1 in Cancer.
J. Caramel (2018)
10.4103/aja.aja_61_17
The transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines
O. Orellana-Serradell (2018)
Determining the Predictive Mechanism of Toxicity Using a Single‐Well Multiplexed Assay
S. Schultz (2018)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar